Immunogenicity and safety of inactivated TZ84- vs. HM175-based hepatitis A vaccines in pediatric populations: A systematic review and meta-analysis.

Hum Vaccin ImmunotherSep 10, 2026 (epub)
Clinical ResearchPediatrics

Ritabrata Kundu, Apurba Ghosh, Archana Toppo et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the immunogenicity and safety of TZ84- vs. HM175-based hepatitis A vaccines in children and adolescents. Analyzing data from four randomized cohorts with 3,282 participants, the study found that TZ84-based vaccines had significantly higher seroconversion rates (OR: 3.05) and geometric mean concentrations (SMD: 0.88) compared to HM175-based vaccines, with similar safety profiles.

Key findings

  • TZ84-based vaccines showed higher seroconversion rates at 1 month (OR: 3.05) compared to HM175-based vaccines.
  • Geometric mean concentrations at 7 months were significantly higher for TZ84-based vaccines (SMD: 0.88).
  • Long-term follow-up indicated greater antibody persistence for TZ84-based vaccines, lasting up to 186 months.
  • Adverse events were comparable between both vaccine types (RR: 0.95).

Why it matters

Understanding the differences in immunogenicity and safety between hepatitis A vaccines is crucial for pediatric vaccination strategies. Higher antibody responses and persistence with TZ84-based vaccines may enhance long-term protection in children and adolescents.

What to keep in mind

The evidence is limited by a small number of unique randomized cohorts and geographic concentration in China.

Source

PubMed · PMID 42721116

Published in Hum Vaccin Immunother. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.